Cassava Sciences announced a 33% workforce reduction, cost-cutting measures, and anticipated topline data release from its Phase 3 REFOCUS-ALZ study of simufilam for Alzheimer’s diseaseAlzheimer’s disease in late Q1/early Q2 2025. This follows the failure of its Phase 3 RETHINK-ALZ study to meet primary endpoints in November 2024. The company held $128.6 million in cash and cash equivalents at the end of 2024.
The upcoming REFOCUS-ALZ data is crucial for determining the future of simufilam. While RETHINK-ALZ’s failure significantly dampened the drug’s prospects, REFOCUS-ALZ, with its larger patient population and longer study duration, presents a final opportunity to demonstrate simufilam’s efficacy. The results will dictate whether further development of simufilam is scientifically and financially viable. For the Alzheimer’s community, the data carries significant weight as the search for effective treatments continues.
Cassava Sciences implemented cost-cutting measures, including a workforce reduction of 10 employees (33%), and discontinued biomarker analysis from previous Phase 2 trials. The company expects a one-time cost of approximately $0.4 million related to the workforce reduction in Q1 2025. These actions, combined with the existing cash reserves, aim to extend the company’s runway as it awaits the REFOCUS-ALZ results.
The release of the REFOCUS-ALZ data represents a pivotal moment for Cassava Sciences. Positive results, although unlikely after the RETHINK-ALZ failure, could potentially revitalize the simufilam program. However, negative data will likely lead to the termination of simufilam development and force the company to reassess its strategic direction. The outcome will heavily influence the future of the company and have implications for the broader Alzheimer’s drug development landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
